Probiotics play an important role in maintaining gut health by modulating the composition of the gut microbiota. BIOVITA 3 is a blend of freeze-dried powders of three probiotics including Clostridium butyricum IDCC 1301, Weizmannia coagulans IDCC 1201, and Bacillus subtilis IDCC 1101. Previous research has shown that this probiotic blend can relieve constipation in mice by rebalancing gut microbes, suggesting its potential benefits for conditions like inflammatory bowel disease (IBD). To explore this possibility, we conducted an experiment examining BIOVITA 3's effect on colitis induced by dextran sulfate sodium (DSS) in mice. For this purpose, mice were orally administered BIOVITA 3 (1 × 106 CFU) or starch (38 mg/mL)once daily for three weeks, followed by replacing a drinking water with 3% DSS in water with unrestricted access for seven days. The onset of colitis was evident through significant increases in the scores of disease activity index (DAI), levels of pro-inflammatory proteins in colon tissues, and damage scores of colon tissues observed through histology. Among these markers of inflammation, the DAI scores and levels of pro-inflammatory proteins (interleukin [IL]-6, interferon-γ, IL-17, leukotriene B4, and myeloperoxidase) were significantly reduced in the group treated with BIOVITA 3 compared to the starch-treated group. These findings support that BIOVITA 3 mitigates symptoms associated with DSS-induced colitis in mice, suggesting its potential therapeutic benefits for IBD.
Probiotics play an important role in maintaining gut health by modulating the composition of the gut microbiota. BIOVITA 3 is a blend of freeze-dried powders of three probiotics including Clostridium butyricum IDCC 1301, Weizmannia coagulans IDCC 1201, and Bacillus subtilis IDCC 1101. Previous research has shown that this probiotic blend can relieve constipation in mice by rebalancing gut microbes, suggesting its potential benefits for conditions like inflammatory bowel disease (IBD). To explore this possibility, we conducted an experiment examining BIOVITA 3's effect on colitis induced by dextran sulfate sodium (DSS) in mice. For this purpose, mice were orally administered BIOVITA 3 (1 × 106 CFU) or starch (38 mg/mL)once daily for three weeks, followed by replacing a drinking water with 3% DSS in water with unrestricted access for seven days. The onset of colitis was evident through significant increases in the scores of disease activity index (DAI), levels of pro-inflammatory proteins in colon tissues, and damage scores of colon tissues observed through histology. Among these markers of inflammation, the DAI scores and levels of pro-inflammatory proteins (interleukin [IL]-6, interferon-γ, IL-17, leukotriene B4, and myeloperoxidase) were significantly reduced in the group treated with BIOVITA 3 compared to the starch-treated group. These findings support that BIOVITA 3 mitigates symptoms associated with DSS-induced colitis in mice, suggesting its potential therapeutic benefits for IBD.